Telix Pharmaceuticals Limited

78 articles with Telix Pharmaceuticals Limited

• FDA Approves Expanded Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Directed Radioligand Therapy

  3/16/2023

  Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States Food and Drug Administration (FDA) has approved a supplementary New Drug Application (sNDA) for Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) to enable its use for the selection of patients with metastatic prostate cancer, for whom 177Lu 177 PSMA-directed therapy is indicated.

• Telix 2022 Full Year Results: Revenue up 20x in first year of commercial sales, underpins transition to cash flow positive

  2/27/2023

  Telix Pharmaceuticals Limited announces its financial results for the financial year ended 31 December 2022.

• Detailed Results from Telix's ZIRCON Phase III Kidney Cancer Imaging Study Presented at ASCO GU

  2/19/2023

  Telix Pharmaceuticals Limited announces detailed positive results from its completed pivotal Phase III ZIRCON trial.

• Telix Collaboration on Next Generation Urologic-Oncology Theranostic Published in Journal of Nuclear Medicine

  2/14/2023

  Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the successful completion of its joint research project conducted with Heidelberg University Hospital (UKHD) under the Research Cooperation Agreement announced in February 2021.

• Telix Reports Fourth Quarter 2022 Financial Results

  1/17/2023

  Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 31 December 2022 (Q4 2022).

• Presentation to J.P. Morgan Healthcare Conference and Q4 2022 Illuccix Revenue Update

  1/8/2023

  Telix Pharmaceuticals Limited advises it is presenting at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco.

• ZIRCON Phase III Renal Cancer Study to be Presented at ASCO GU along with Theranostic Pipeline Advances

  12/21/2022

  Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the completed pivotal Phase III ZIRCON study (ClinicalTrials.gov Identifier: NCT03849118) of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) has been selected for oral presentation at the upcoming 2023 ASCO GU Symposium to be held in San Francisco, CA, from February 16-18 2023.

• Telix Announces Executive Leadership Appointments

  12/4/2022

  Telix Pharmaceuticals Limited announces several key executive leadership appointments and promotions, reflecting the increased commercial focus of the Company and ongoing succession planning.

• Illuccix® Available on High Activity Gallium Generator Technology to Meet High Demand

  11/22/2022

  Telix Pharmaceuticals Limited announces Illuccix® with up to 50mCi for radiolabeling is available for use on 100mCi gallium generators, an important development in radioisotope production.

• First Patient Dosed in Phase II 'IPAX-Linz' Study of TLX101 for Glioblastoma Therapy

  11/21/2022

  Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in a Phase II investigator-initiated study of TLX101 in combination with external beam radiation therapy (EBRT) in patients with recurrent high-grade gliomas (HGG), including glioblastoma multiforme (GBM).

• Telix Acquires Optimal Tracers

  11/13/2022

  Telix Pharmaceuticals Limited announces that it has entered into an agreement with Sacramento-based Northern California PET Imaging Center to acquire Optimal Tracers, a radiochemistry development business providing radiochemistry process development services and research tracers for use in clinical trials.

• Telix to Present at Jefferies London Healthcare Conference 2022

  11/11/2022

  Telix Pharmaceuticals Limited advises that Dr Christian Behrenbruch , Group CEO and Managing Director, will be presenting at the Jefferies London Healthcare Conference 2022.

• Telix Announces Positive Topline Results of ZIRCON Phase III Kidney Cancer Imaging Study

  11/7/2022

  Telix Pharmaceuticals Limited today announced highly positive top-line results from the pivotal Phase III ZIRCON study (Zirconium in Renal Cancer Oncology, NCT03849118) of its investigational renal (kidney) cancer positron emission tomography (PET) imaging agent, TLX250-CDx (89Zr-DFO-girentuximab). The study has met its co-primary and secondary endpoints.

• Telix Reports Third Quarter 2022 Financial Results

  10/19/2022

  Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 30 September 2022 (Q3 2022).

• Chinese NMPA Approves Pivotal Phase III Study of TLX591-CDx for Prostate Cancer Imaging

  10/16/2022

  Telix Pharmaceuticals Limited announces that the Chinese National Medical Products Administration Center for Drug Evaluation has approved an investigational new drug application to commence a pivotal Phase III registration study of TLX591-CDx, for the imaging of prostate cancer using Positron Emission Tomography that will bridge to the marketing authorisation granted to Illuccix® by the United States Food and Drug Administration.

• Health Canada Approves Illuccix® for Prostate Cancer Imaging

  10/13/2022

  Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces that Health Canada has approved Illuccix® [kit for the preparation of gallium (68Ga) gozetotide injection] for use in staging and re-staging intermediate and high-risk prostate cancer and localizing tumour tissue in recurrent prostate cancer.

• Chinese NMPA Approves Study of Telix Kidney Cancer Imaging Candidate

  9/27/2022

  Telix Pharmaceuticals Limited announces that the Chinese National Medical Products Administration Center for Drug Evaluation has approved a pivotal Phase III registration study that will bridge to Telix's global Phase III 'ZIRCON' trial of TLX250-CDx, for the imaging of clear cell renal cell carcinoma with position emission tomography.

• First Patient Enrolled in ProstACT TARGET Study

  9/26/2022

  Telix Pharmaceuticals Limited and GenesisCare today announce that a first patient has been enrolled in the Phase II ProstACT TARGET study of Telix's prostate cancer antibody therapy candidate TLX591 (177Lu-DOTA-rosopatamab), in patients experiencing a first recurrence of prostate-specific antigen (PSA) after initial therapy for prostate cancer.

• Final IPAX-1 Study Data Confirms Safety and Tolerability Profile for TLX101, Preliminary Efficacy Data

  9/20/2022

  Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today reports the final results from the IPAX-1 Ph I/II study of TLX101 therapy (4-L-[ 131I] iodo-phenylalanine, or 131I-IPA) in combination with external beam radiation therapy (EBRT) in recurrent glioblastoma multiforme (GBM).

• Telix APAC Report: Regulatory Progress for Prostate and Kidney Cancer Imaging

  8/1/2022

  Telix Pharmaceuticals Limited reports on regulatory progress for the Company's core prostate and kidney cancer imaging programs in the Asia Pacific Operating Region, including progress in the major market of China with its strategic partner Grand Pharmaceutical Group Limited.